Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
Chiara Degirolamo, Carlo Sabbà, Antonio Moschetta
Nature Reviews Drug Discovery (2015) Vol. 15, Iss. 1, pp. 51-69
Closed Access | Times Cited: 381

Showing 1-25 of 381 citing articles:

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque, et al.
The Lancet Oncology (2020) Vol. 21, Iss. 5, pp. 671-684
Open Access | Times Cited: 1264
Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics
Patrycja Puchalska, Peter A. Crawford
Cell Metabolism (2017) Vol. 25, Iss. 2, pp. 262-284
Open Access | Times Cited: 1258
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 683
Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
Varman T. Samuel, Gerald I. Shulman
Cell Metabolism (2017) Vol. 27, Iss. 1, pp. 22-41
Open Access | Times Cited: 608
FGF/FGFR signaling in health and disease
Yangli Xie, Nan Su, Jing Yang, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 594
Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance
Ruth C. R. Meex, Matthew J. Watt
Nature Reviews Endocrinology (2017) Vol. 13, Iss. 9, pp. 509-520
Closed Access | Times Cited: 539
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
Leiluo Geng, Karen S.L. Lam, Aimin Xu
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 11, pp. 654-667
Closed Access | Times Cited: 448
Pathology of Human Coronary and Carotid Artery Atherosclerosis and Vascular Calcification in Diabetes Mellitus
Kazuyuki Yahagi, Frank D. Kolodgie, Christoph Lutter, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2016) Vol. 37, Iss. 2, pp. 191-204
Open Access | Times Cited: 436
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Stephen A. Harrison, Mary E. Rinella, Manal F. Abdelmalek, et al.
The Lancet (2018) Vol. 391, Iss. 10126, pp. 1174-1185
Closed Access | Times Cited: 381
Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment
Yanyun Gu, Xiaokai Wang, Junhua Li, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 361
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)
Masaru Katoh
International Journal of Molecular Medicine (2016) Vol. 38, Iss. 1, pp. 3-15
Open Access | Times Cited: 342
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 338
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Vincenzo Mazzaferro, Bassel F. El‐Rayes, Michele Droz Dit Busset, et al.
British Journal of Cancer (2018) Vol. 120, Iss. 2, pp. 165-171
Open Access | Times Cited: 326
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion–Positive Intrahepatic Cholangiocarcinoma
Lipika Goyal, Lei Shi, Leah Y. Liu, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1064-1079
Open Access | Times Cited: 320
Bile Acids as Metabolic Regulators and Nutrient Sensors
John Y.L. Chiang, Jessica M. Ferrell
Annual Review of Nutrition (2019) Vol. 39, Iss. 1, pp. 175-200
Open Access | Times Cited: 318
Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors
Shuyan Dai, Zhan Zhou, Zhuchu Chen, et al.
Cells (2019) Vol. 8, Iss. 6, pp. 614-614
Open Access | Times Cited: 242
Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System
Kim L. Mertens, Andries Kalsbeek, Maarten R. Soeters, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 240
The ever-expanding myokinome: discovery challenges and therapeutic implications
Martin Whitham, Mark A. Febbraio
Nature Reviews Drug Discovery (2016) Vol. 15, Iss. 10, pp. 719-729
Closed Access | Times Cited: 235
Fibroblast Growth Factor 21—Metabolic Role in Mice and Men
Harald Staiger, Michaela Keuper, Lucia Berti, et al.
Endocrine Reviews (2017) Vol. 38, Iss. 5, pp. 468-488
Open Access | Times Cited: 233
NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Stephen J. Rossi, Angelo H. Paredes, et al.
Hepatology (2019) Vol. 71, Iss. 4, pp. 1198-1212
Open Access | Times Cited: 233
Targeting the alternative bile acid synthetic pathway for metabolic diseases
Jia Wang, Meilin Wei, Cynthia Rajani, et al.
Protein & Cell (2020) Vol. 12, Iss. 5, pp. 411-425
Open Access | Times Cited: 230
Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis
Stephen A. Harrison, Guy Neff, Cynthia D. Guy, et al.
Gastroenterology (2020) Vol. 160, Iss. 1, pp. 219-231.e1
Open Access | Times Cited: 229
Genetic insights into the mechanisms of Fgf signaling
J. Richard Brewer, Pierre Mazot, Philippe Soriano
Genes & Development (2016) Vol. 30, Iss. 7, pp. 751-771
Open Access | Times Cited: 216
Bile acid metabolism and signaling, the microbiota, and metabolic disease
Jingwei Cai, Bipin Rimal, Changtao Jiang, et al.
Pharmacology & Therapeutics (2022) Vol. 237, pp. 108238-108238
Open Access | Times Cited: 211
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Sangwon Lee, Jungyuen Choi, Jyotidarsini Mohanty, et al.
Nature (2018) Vol. 553, Iss. 7689, pp. 501-505
Open Access | Times Cited: 198
Page 1 - Next Page

Scroll to top